Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
Launched by CLOVER BIOPHARMACEUTICALS AUS PTY · Jan 10, 2022
Trial Information
Current as of May 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female participants at least 18 years of age;
- • Individuals willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests, and other study procedures;
- • Individuals willing and able to give an informed consent, prior to screening;
- • Healthy participants or participants with pre-existing medical conditions who are in a stable medical condition;
- • Individuals who received primary vaccination series with one of the selected COVID-19 vaccines (Comirnaty, Vaxzevria, or CoronaVac) ≥3 months prior to enrollment; or received primary series and a booster dose (≥3 months after primary series) of CoronaVac, ≥3 months prior to enrollment.
- Exclusion Criteria:
- • Individuals with fever \>37.5°C (axillary), or any acute illness at baseline (Day 1) or within 3 days prior to randomization;
- • Individuals with laboratory-confirmed SARS-CoV-2 infection at Visit 1 (determined by positive Rapid Antigen Test or RT-PCR);
- • Individuals who have received an investigational or licensed COVID-19 vaccine prior to Day 1 (except for primary series with Comirnaty, Vaxzevria, CoronaVac vaccines, or primary and booster dose of CoronaVac), or plan to receive COVID-19 vaccine during the study period;
- • Individuals who have a history of severe adverse reaction associated with a vaccine or severe allergic reaction (e.g., anaphylaxis) to any component of the study vaccines;
- • Individuals who have received any other investigational product within 30 days prior to Day 1 or intend to participate in another clinical study at any time during the conduct of this study.
About Clover Biopharmaceuticals Aus Pty
Clover Biopharmaceuticals AUS Pty is an innovative biotechnology company focused on the development and commercialization of advanced therapeutic solutions for infectious diseases and cancer. Leveraging its proprietary protein-based vaccine technology, Clover aims to address unmet medical needs through the rapid development of safe and effective treatments. With a strong commitment to scientific excellence and patient-centric approaches, Clover Biopharmaceuticals AUS Pty is dedicated to advancing healthcare outcomes and contributing to global public health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manila, Metro Manila, Philippines
Las Piñas, Metro Manila, Philippines
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials